...
inkt-img

Mink Therapeutics Inc, Common Stock

INKT

NAQ

$0.512

+$0.05

(10.79%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$18.32M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
41.84K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.05
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.46 L
$1.9 H
$0.512

About Mink Therapeutics Inc, Common Stock

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINKTSectorS&P500
1-Week Return-28.74%-3.39%-3.47%
1-Month Return-33.35%-3.25%-0.29%
3-Month Return-37.41%-11.61%4.5%
6-Month Return-47.19%-5.89%6.91%
1-Year Return-54.59%2.65%23.79%
3-Year Return-89.57%0.56%28.43%
5-Year Return-96.14%34.63%83.64%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue689.63K--2.70B-[{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-55.06K28.36B30.95B204.62K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":91.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit689.63K(55.06K)(28.36B)(28.24B)(204.62K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.98,"profit":false},{"date":"2021-12-31","value":-4112169.64,"profit":false},{"date":"2022-12-31","value":-4095630.82,"profit":false},{"date":"2023-12-31","value":-29.67,"profit":false}]
Gross Margin100.00%--(1044.26%)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1044.26,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses23.48M10.80M18.61M30.95M22.92M[{"date":"2019-12-31","value":75.87,"profit":true},{"date":"2020-12-31","value":34.89,"profit":true},{"date":"2021-12-31","value":60.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.06,"profit":true}]
Operating Income(22.28M)(14.64M)(28.36M)(30.95M)(22.92M)[{"date":"2019-12-31","value":-2228447800,"profit":false},{"date":"2020-12-31","value":-1463718600,"profit":false},{"date":"2021-12-31","value":-2835859100,"profit":false},{"date":"2022-12-31","value":-3094927800,"profit":false},{"date":"2023-12-31","value":-2292110500,"profit":false}]
Total Non-Operating Income/Expense(3.08M)(4.04M)(4.29M)3.21M1.02M[{"date":"2019-12-31","value":-95.86,"profit":false},{"date":"2020-12-31","value":-125.88,"profit":false},{"date":"2021-12-31","value":-133.46,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.76,"profit":true}]
Pre-Tax Income(23.80M)(16.24M)(30.21M)(27.99M)(22.46M)[{"date":"2019-12-31","value":-2380218200,"profit":false},{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false}]
Income Taxes2.11M(560.38K)(7.10M)(3.21M)3.00[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-26.53,"profit":false},{"date":"2021-12-31","value":-336.1,"profit":false},{"date":"2022-12-31","value":-152.05,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(25.91M)(15.68M)(23.11M)(24.78M)(22.46M)[{"date":"2019-12-31","value":-2591428500,"profit":false},{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245786200,"profit":false}]
Income From Continuous Operations(23.80M)(16.24M)(30.21M)(27.99M)(24.77M)[{"date":"2019-12-31","value":-2380218200,"profit":false},{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2476900100,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(25.91M)(15.68M)(23.11M)(24.78M)(22.46M)[{"date":"2019-12-31","value":-2591428500,"profit":false},{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false}]
EPS (Diluted)(0.18)(0.70)(1.19)(0.83)(0.66)[{"date":"2019-12-31","value":-17.98,"profit":false},{"date":"2020-12-31","value":-70.44,"profit":false},{"date":"2021-12-31","value":-119.06,"profit":false},{"date":"2022-12-31","value":-83,"profit":false},{"date":"2023-12-31","value":-66,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INKT
Cash Ratio 855.28
Current Ratio 888.66

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INKT
ROA (LTM) -97.25%
ROE (LTM) -1238.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INKT
Debt Ratio Lower is generally better. Negative is bad. 3.38
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.38

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INKT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 10.05
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Mink Therapeutics Inc share price today?

Mink Therapeutics Inc (INKT) share price today is $0.512

Can Indians buy Mink Therapeutics Inc shares?

Yes, Indians can buy shares of Mink Therapeutics Inc (INKT) on Vested. To buy Mink Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mink Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Mink Therapeutics Inc (INKT) via the Vested app. You can start investing in Mink Therapeutics Inc (INKT) with a minimum investment of $1.

How to invest in Mink Therapeutics Inc shares from India?

You can invest in shares of Mink Therapeutics Inc (INKT) via Vested in three simple steps:

  • Click on Sign Up or Invest in INKT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mink Therapeutics Inc shares
What is Mink Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Mink Therapeutics Inc (INKT) is $1.9. The 52-week low price of Mink Therapeutics Inc (INKT) is $0.46.

What is Mink Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Mink Therapeutics Inc (INKT) is

What is Mink Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mink Therapeutics Inc (INKT) is 10.05

What is Mink Therapeutics Inc dividend yield?

The dividend yield of Mink Therapeutics Inc (INKT) is 0.00%

What is the Market Cap of Mink Therapeutics Inc?

The market capitalization of Mink Therapeutics Inc (INKT) is $18.32M

What is Mink Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Mink Therapeutics Inc is INKT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top